Propanc’s PRP Shows 90% Tumor Growth Inhibition in Pancreatic Cancer Models, Targeting Untapped Biology

  • Propanc Biopharma reported preclinical data showing >90% tumor growth inhibition with PRP in pancreatic cancer models, contrasting with Revolution Medicines’ approved daraxonrasib.
  • PRP demonstrated >2.5-fold median survival extension, reduced metastatic burden, and tumor microenvironment remodeling in PDAC models.
  • Propanc plans to initiate a Phase 1b first-in-human study of PRP in Q1 2027 across Australia for advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers.
  • PRP holds FDA Orphan Drug Designation for pancreatic cancer and is not restricted to RAS genotype, unlike daraxonrasib.

Propanc’s PRP represents a novel approach to pancreatic cancer treatment, addressing limitations of existing RAS-targeted therapies by focusing on tumor microenvironment remodeling and metastatic suppression. The upcoming Phase 1b study will be critical in validating PRP’s potential as a combination or sequential therapy in a disease with high unmet need. The contrast with Revolution Medicines’ daraxonrasib highlights the strategic opportunity to target complementary biological pathways in PDAC.

Combination Strategy
Whether PRP can establish itself as a complementary therapy to RAS inhibitors like daraxonrasib, targeting untapped biology in pancreatic cancer.
Clinical Translation
The pace at which preclinical efficacy translates into human outcomes in the upcoming Phase 1b study.
Regulatory Pathway
How Propanc navigates the Orphan Drug Designation status to accelerate PRP’s development and potential approval.